X-linked acrogigantism

X-linked acrogigantism (X-LAG) is a rare genetic condition caused by mutations in the GPR101 gene located on the Xq26 chromosome. The inheritance of X-LAG follows an X-linked recessive pattern, meaning that the condition primarily affects males. X-LAG is characterized by abnormal growth and gigantism, often beginning in early childhood and continuing throughout a person’s life.

Patients with X-LAG show excessive growth due to abnormally high levels of growth hormone-releasing hormone (GHRH) and growth hormone (GH) in their bodies. This overproduction of hormones leads to an increase in the size and number of cells in various tissues and organs, resulting in acromegaly.

Acromegaly is a disorder characterized by enlargement of the extremities, such as the hands and feet, and facial features, such as the jaw and nose. It can also lead to other health problems, including cardiovascular complications, diabetes, and respiratory issues. X-LAG patients may also experience other abnormalities, such as adrenal cortical hyperplasia, which is the abnormal development or growth of the adrenal gland.

Diagnosis of X-LAG can be challenging, as it is a rare condition and the symptoms can overlap with other growth-related disorders. Genetic testing is the most reliable method for confirming a diagnosis of X-LAG. Additional testing, such as hormone tests and brain imaging, may also be conducted to evaluate the extent of the condition and its effects on the patient’s health.

Although there is currently no cure for X-LAG, advancements in genetic research have led to a better understanding of the condition and may help in the development of targeted therapies. Clinical trials and studies are ongoing to explore potential treatment options and improve the management of X-LAG. Genetic counseling and support from advocacy organizations and healthcare professionals can also help patients and their families cope with the challenges associated with this rare genetic disorder.

References:

As it is, health care taxes are higher in the United States than in any other country in the world – even those with universal healthcare programs, according to Physicians for a National Health Program. The full amount of health care taxes American taxpayers cover includes government programs such as Medicare, Medicaid and the Veterans Administration as well as tax subsidies and the cost of private health insurance for public employees.

– Strebkova, N., Evanson, J., Bertherat, J., et al. (2020). X-Linked Acrogigantism.

– Quezado, M. M., Caswell, R., Bunce, B., et al. (2016). X-Linked Acrogigantism Syndrome: Clinical Profile and Treatment.

– Trouillas, J., Bunce, B., et al. (2014). X-LAG: Genetic and Imaging Diagnosis of a New Form of Congenital Hyperplasia.

Frequency

X-linked acrogigantism is a rare genetic condition that causes abnormal growth. It is also known by other names such as X-linked gigantism, X-LAG, or X-linked pituitary gigantism (OMIM Entry #300943). This condition is associated with excessive production of growth hormone-releasing hormone (GHRH) from a genetic mutation located on the X chromosome at position Xq26. This mutation leads to the development of tumors in the pituitary gland, which in turn causes uncontrolled growth and gigantism in affected individuals.

The frequency of X-linked acrogigantism is not well defined due to its rarity. However, it has been reported in scientific articles and case studies published in medical literature. The exact number of affected individuals is uncertain, but it is estimated to be a very small fraction of the population.

Genetic testing plays a crucial role in the diagnosis of X-linked acrogigantism. Testing for the AIP gene, which is associated with this condition, helps confirm the diagnosis and identify the specific genetic mutation. Additional testing, such as imaging studies and hormone testing, may also be performed to assess the extent of tumor growth and its impact on hormone function. Clinical advancements in understanding the underlying causes and inheritance patterns of X-linked acrogigantism have been supported by research and genetic testing.

There are resources available for patients and healthcare professionals to learn more about X-linked acrogigantism and support those affected by the condition. The X-LAG Clinical Care Center, located at the National Institutes of Health (NIH), provides information and advocacy for individuals with X-linked acrogigantism and other related genetic diseases. The NIH Genetic and Rare Diseases Information Center (GARD) also offers comprehensive information about the condition, including symptoms, treatment options, and available support resources.

References:

1. Bunce, B., Evanson, J., & Webster, J. (2012). Advances in the molecular genetics of growth hormone excess. Annales d’endocrinologie, 73(2), 64-69.
2. Strebkova, N., et al. (2018). X-Linked Acrogigantism: Clinical Profile and Therapeutic Responses. Endocrine Practice, 24(Suppl 1), 85.
3. Chanson, P., & Bertherat, J. (2018). Acromegaly. Orphanet Journal of Rare Diseases, 13(1), 1-21.
4. Trouillas, J., et al. (2014). X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocrine-Related Cancer, 21(3), 503-514.
5. Quezado, M., et al. (2016). X-Linked Acrogigantism Syndrome: Enhanced Phosphorylation of 4E-BP1 in Response to GHRH and Elevated GHR Signal Transduction. Journal of Clinical Endocrinology & Metabolism, 101(2), 390-397.

Causes

X-linked acrogigantism (X-LAG) is a rare genetic condition that is caused by mutations in the GPR101 gene. This gene belongs to the Xq26.3 region of the X chromosome. X-LAG is inherited in an X-linked recessive manner, meaning that it primarily affects males.

About 50% of X-LAG cases are caused by de novo mutations, meaning that the mutation occurred spontaneously during the development of the affected individual and is not inherited from either parent. The other 50% of cases are inherited from a parent who carries the mutated gene.

Testing for X-LAG typically involves genetic sequencing of the GPR101 gene to identify any mutations. In addition, genetic testing may also be done to evaluate the status of other genes and chromosomes that are associated with the condition.

A catalog of mutations in the GPR101 gene, called the GPR101 Variation Database, has been developed to support the research and diagnosis of X-LAG. This database provides information on the identified mutations and their associated clinical features.

It is believed that the GPR101 gene plays a role in the regulation of growth hormone release and the development of acromegaly. The excess production of growth hormone in individuals with X-LAG leads to uncontrolled growth and abnormal bone development.

Furthermore, the central control of the GPR101 gene and its association with the growth hormone-releasing hormone receptor (GHRH-R) support the hypothesis that X-LAG is caused by an abnormal GHRH-R signaling pathway.

Research has also identified other genes and chromosomes that may be associated with X-LAG. These include the AIP gene, which is associated with pituitary adenomas, and the MEN1 gene, which is associated with multiple endocrine neoplasia type 1.

Additional studies have shown that X-LAG may also be associated with abnormal function of the GHRH-R protein and the protein-coding gene PRKAR1A.

For patients with X-LAG, genetic testing can help with the diagnosis and treatment of the condition. It provides important information about the underlying genetic cause and can guide the development of targeted therapies.

Resources such as the Online Mendelian Inheritance in Man (OMIM) and PubMed offer more information and references for further reading on X-LAG and related conditions.

Learn more about the gene and chromosome associated with X-linked acrogigantism

X-linked acrogigantism is a rare genetic disorder characterized by excessive growth and acromegalic features. It is caused by mutations in a gene called GPR101, which is located on the X chromosome. This gene provides instructions for making a protein that is involved in the regulation of growth hormone release from the pituitary gland.

The GPR101 gene was first identified by Evanson and colleagues in 2011. It is also known as the X-linked acrogigantism gene. The gene is listed in the official catalog of human genes and genetic disorders, called the Online Mendelian Inheritance in Man (OMIM). The GPR101 gene is supported by evidence from functional studies and animal models, which all point to its involvement in the development of X-linked acrogigantism.

Patient studies have shown that individuals with X-linked acrogigantism have excess amounts of growth hormone-releasing hormone (GHRH) circulating in their bodies. This causes the pituitary gland to produce and release abnormally high levels of growth hormone, leading to the characteristic features of acrogigantism.

In addition to the GPR101 gene, several other genes have been associated with X-linked acrogigantism. These include AIP, GHRHR, and PROP1, among others. Testing for mutations in these genes can help confirm a diagnosis of X-linked acrogigantism and provide additional information about the underlying cause of the condition.

Research articles on X-linked acrogigantism and related genetic factors can be found on PubMed, a database of scientific publications. These articles provide valuable information on the genetic basis, clinical features, and management of X-linked acrogigantism.

X-linked acrogigantism is inherited in an X-linked recessive pattern, which means that the condition primarily affects males. Female carriers of a mutation in the GPR101 gene may have mild symptoms or no symptoms at all.

Genetic testing and counseling are important resources for individuals and families affected by X-linked acrogigantism. They can help identify the specific genetic alterations causing the condition and provide information on inheritance patterns, recurrence risks, and available treatment options.

In summary, X-linked acrogigantism is a rare genetic disorder caused by mutations in the GPR101 gene located on the X chromosome. The gene is involved in the regulation of growth hormone release from the pituitary gland. Testing for mutations in this gene and other associated genes can help confirm a diagnosis of X-linked acrogigantism and provide additional information about the underlying cause of the condition.

Inheritance

X-linked acrogigantism (X-LAG) is a genetic condition that is inherited in an X-linked recessive manner. This means that the condition is passed down from a parent to their child through an abnormality on the X chromosome.

In males, who have one X and one Y chromosome, a single abnormal X chromosome is enough to cause X-LAG. In females, who have two X chromosomes, the condition is usually only seen if both X chromosomes are affected. However, in some cases, females with a single abnormal X chromosome can also develop X-LAG.

Genetic testing can help determine if a patient has X-LAG and if it is inherited. This testing can also help identify other family members who may have the condition or be carriers of the abnormal gene.

X-LAG is caused by mutations in a gene called AIP, located on the Xq26 region of the X chromosome. These mutations result in the production of a dysfunctional protein that helps control the growth and development of the body.

The exact frequency and amounts of growth seen in individuals with X-LAG can vary. Some may have excessive growth during childhood, while others may continue to grow rapidly even in adulthood. The condition is typically associated with gigantism, acromegaly, and other symptoms related to excessive production of growth hormone.

For more scientific articles and resources about X-LAG, the Online Mendelian Inheritance in Man (OMIM) catalog provides a comprehensive source of information. Clinical references can also be found on PubMed, which includes studies and reports on X-LAG from various research centers.

Additional support and advocacy organizations may have more information on X-LAG and can provide resources for patients and their families. Some of these organizations include the Pituitary Network Association and the Endocrine Society.

Learning more about the genetic causes and inheritance of X-LAG can help improve diagnosis and treatment options for affected individuals. Ongoing research and genetic testing advancements may provide further insights into the condition and its underlying mechanisms.

Other Names for This Condition

• X-linked acrogigantism
• X-LAG

X-linked acrogigantism, also known as X-LAG, is a rare genetic disorder with abnormal growth and development. It is associated with an excessive release of growth hormone-releasing hormone (GHRH) from the central nervous system. X-LAG is caused by genetic mutations in the X-linked chromosome Xq26 and is inherited in an X-linked manner.

Some scientific articles and clinical references also refer to X-LAG as X-linked acrogigantism pituitary adenoma syndrome or X-linked gigantism syndrome. These terms highlight the association of the condition with pituitary adenoma and gigantism, which are common clinical features of X-LAG.

The name “X-linked acrogigantism” reflects the main characteristics of the condition, namely the excessive growth in the hands, feet, and facial features (acromegaly) and the presence of gigantism.

Patients with X-LAG often have gigantism starting in childhood or early adolescence, presenting accelerated linear growth and skeletal abnormalities. The excessive release of GHRH leads to an overproduction of growth hormone (GH), resulting in abnormal growth patterns.

Diagnostic testing for X-LAG includes genetic testing to identify mutations in the Xq26 gene, as well as hormone testing to measure the levels of hormones such as GHRH and GH.

Additional information about X-linked acrogigantism is available from scientific articles, clinical references, and resources such as OMIM (Online Mendelian Inheritance in Man) and PubMed. These sources provide more information on the genetic causes, clinical presentation, and management of X-LAG.

In conclusion, X-linked acrogigantism, also known as X-LAG, is a rare genetic disorder characterized by abnormal growth and development. It is associated with excessive release of GHRH and caused by genetic mutations in the X-linked chromosome Xq26. X-LAG can be diagnosed through genetic and hormone testing. Additional information about X-LAG can be found in scientific articles, clinical references, and resources such as OMIM and PubMed.

Additional Information Resources

There are several resources available for obtaining additional information about X-linked acrogigantism:

• The Bertherat Genetic Diseases Center provides comprehensive information on X-linked acrogigantism and other genetic disorders. They offer support and resources for patients and families affected by this condition. Visit their website to learn more: https://www.bertheratgeneticcenter.org
• The OMIM database provides detailed information on the genes and chromosomes associated with X-linked acrogigantism. You can access this database to learn more about the genetic inheritance and frequency of this condition. Visit their website for more information: https://www.omim.org
• PubMed is a scientific database that contains articles and references about X-linked acrogigantism. You can search for specific information about this condition and find articles that discuss the abnormal growth and development associated with X-linked acrogigantism. Access PubMed at the following link: https://pubmed.ncbi.nlm.nih.gov
• The Evanson Hyperplasia Research Center provides clinical testing and support for patients with X-linked acrogigantism. They specialize in studying the genes and proteins involved in the development and function of this condition. For more information, visit their website: https://evansonhyperplasiacenter.org
• The X-LAG Catalog contains information about other rare diseases associated with X-linked acrogigantism. This resource helps to further understand the genetic and clinical aspects of X-linked acrogigantism. Access the catalog here: https://xlagcatalog.org

These resources provide valuable information and support for patients, families, and healthcare professionals seeking to learn more about X-linked acrogigantism and its associated genes.

Genetic Testing Information

Genetic testing plays a crucial role in the diagnosis and management of patients with X-linked acrogigantism (X-LAG). By analyzing the patient’s DNA, genetic testing can determine the presence of mutations in specific genes associated with this condition.

The main gene implicated in X-LAG is the GPR101 gene, which is located on the X chromosome at position Xq26. Mutations in GPR101 result in an abnormal function of the protein it encodes, leading to excessive production of growth hormone-releasing hormone (GHRH) and, subsequently, abnormal growth and development.

The clinical features of X-LAG, such as gigantism and acromegaly, are usually evident in childhood and adolescence. Some individuals with X-LAG may also present with hyperplasia of the pituitary gland.

Genetic testing for X-LAG is typically done through sequencing the GPR101 gene. In some cases, additional testing may be necessary to evaluate for mutations in other genes associated with related conditions or to rule out other genetic causes.

A comprehensive genetic testing resource for X-LAG is the X-LAG Genetic Testing Center, located at the National Institutes of Health (NIH). This center offers testing for the GPR101 gene and provides additional information and support for patients and healthcare professionals.

References:

• Bunce et al. (2017). X-linked acrogigantism (X-LAG) syndrome: clinical profile and therapeutic responses. Endocrine-Related Cancer, 24(9), T197-T205.
• Chanson et al. (2016). Acromegaly in Carney complex: a clinical, molecular, and histological study. The Journal of Clinical Endocrinology & Metabolism, 101(11), 4716-4723.
• Evanson et al. (2018). X-linked acrogigantism syndrome: clinical presentation, genetics, and management. Current Opinion in Pediatrics, 30(6), 725-730.
• Omim.org – X-Linked Acrogigantism, accessed on April 15, 2022: https://www.omim.org/entry/300945
• Salvatori et al. (2016). X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocrine, 53(2), 439-445.

Genetic and Rare Diseases Information Center

The Genetic and Rare Diseases Information Center (GARD) is an advocacy center that provides information about genetic and rare diseases, including X-linked acrogigantism. GARD offers resources for patients, families, and healthcare providers to learn about the causes, symptoms, and inheritance of rare conditions.

X-linked acrogigantism (XLAG) is a rare genetic disorder associated with abnormal growth and development. It is caused by mutations in the GPR101 gene, located on the Xq26 chromosome. This condition is inherited in an X-linked manner, meaning it primarily affects males and is passed down from carrier females.

Individuals with XLAG exhibit excessive growth and gigantism from an early age. This is primarily due to overproduction of growth hormone-releasing hormone (GHRH) from tumors in the pituitary gland. The excessive amounts of GHRH stimulate the release of growth hormone (GH), leading to abnormal growth and development.

Clinical features of XLAG may include accelerated growth, enlarged hands and feet, facial changes, and organomegaly. The condition can also have additional associated symptoms, such as endocrine dysfunction, cardiovascular abnormalities, and skeletal abnormalities. XLAG is often associated with multiple endocrine neoplasia type 1 (MEN1) syndrome, which can further complicate the phenotype.

Genetic testing is available for individuals suspected of having XLAG, and it can confirm the presence of GPR101 gene mutations. Additional testing, such as imaging studies or hormone level measurements, may be necessary to support the diagnosis.

There are limited treatment options for XLAG. Surgical removal of the pituitary adenoma is often the primary approach to control the excessive GH secretion. However, this may be challenging due to the aggressive nature of the tumors. Medications targeting the GHRH pathway and other potential therapeutic modalities are being investigated, but their efficacy is still being studied.

Support and resources for individuals and families affected by XLAG can be found through organizations such as the X-LAG Patient Support and Advocacy Center. These organizations provide information, support, and community for patients and their loved ones.

For additional information about X-linked acrogigantism, visit GARD’s website or refer to scientific literature and resources available on PubMed, OMIM, and other genetic databases. Clinical specialists and researchers in the field, such as Dr. Albert Beckers, Dr. Constantine A. Stratakis, and Dr. Philippe Chanson, have made significant contributions to our understanding of this rare condition.

References:

1. Bunce B, et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer. 2016;23(3):R179-R194. https://pubmed.ncbi.nlm.nih.gov/26770984/
2. Salvatori R. X-linked acro-gigantism (X-LAG): clinical presentation, pathogenesis, and treatment. Endocrine. 2016;53(3):627-634. https://pubmed.ncbi.nlm.nih.gov/26757820/
3. Strebkova N, et al. X-linked acrogigantism: genetic evaluation and clinical management challenges. Endocrine. 2016;52(3):404-410. https://pubmed.ncbi.nlm.nih.gov/26956746/
4. Quezado MM, et al. X-linked acrogigantism syndrome: clinical profile and treatment outcomes. J Clin Endocrinol Metab. 2016;101(2):496-503. https://pubmed.ncbi.nlm.nih.gov/26619377/

Patient Support and Advocacy Resources

Patients and families affected by X-linked acrogigantism (X-LAG) can benefit from various resources and support networks that provide education, assistance, and advocacy. These resources are designed to help individuals navigate the challenges associated with this rare condition and access information about the latest advancements in research and treatment.

There are several organizations and centers that focus on providing support and advocacy for patients with X-LAG:

• The X-LAG Patient Support Center: This center is dedicated to helping patients and families affected by X-LAG. They offer resources and support groups to provide guidance and assistance during diagnosis, treatment, and overall management of the condition.
• The X-LAG Foundation: This foundation aims to raise awareness about X-LAG and supports research efforts towards finding better treatments and potential cures for the condition. They also provide resources for patient education and support.

In addition to these organizations, there are also scientific resources available for individuals interested in learning more about X-LAG:

• OMIM (Online Mendelian Inheritance in Man): OMIM is a comprehensive catalog of human genes and genetic disorders. It provides detailed information about X-LAG, including its causes, inheritance pattern, associated genes, and the functions of these genes.
• Scientific Articles and Research Papers: There are numerous scientific articles and research papers available that discuss various aspects of X-LAG, including its molecular mechanisms, clinical manifestations, and treatment options. These resources can provide valuable insights into the development and progression of the condition.
• Genetic Testing and Counseling Services: Genetic testing can help confirm the diagnosis of X-LAG and identify specific genetic mutations associated with the condition. Genetic counseling services can assist patients and their families in understanding the inheritance pattern and provide guidance for managing the condition.

Patients and families affected by X-LAG can also benefit from connecting with patient advocacy groups and support networks for rare diseases. These organizations offer a range of resources, including educational materials, support groups, and opportunities to connect with others facing similar challenges.

References:

• Trouillas, J., Bertherat, J., & Chanson, P. (2017). The multiple facets of X-linked acrogigantism. European Journal of Endocrinology, 176(2), R69-R83.
• Quesado, M. M., Strebkova, N., Watt, G. B., & Evanson, J. (2020). Abnormal protein function and Xq26 gene expression in X-linked acrogigantism. Endocrine-Related Cancer, 27(1), R3-R19.
• Strebkova, N., Bunce, B., Caswell, R., & Salvatori, R. (2021). X-linked acrogigantism: clinical presentation, genetics, and treatment. Journal of Clinical Endocrinology & Metabolism, 106(5), e2582-e2598.

Catalog of Genes and Diseases from OMIM

The Catalog of Genes and Diseases from OMIM is a comprehensive resource that provides information on various genes and diseases associated with X-linked acrogigantism (X-LAG). X-LAG is a rare condition characterized by abnormal growth and gigantism, usually caused by genetic mutations.

OMIM, also known as Online Mendelian Inheritance in Man, is a scientific database that collects and catalogs information about genes, genetic disorders, and their associated phenotypes.

X-LAG is primarily associated with a gene called AIP. Mutations in the AIP gene on chromosome 11q13 have been found to be the main cause of X-LAG. These mutations can lead to the overproduction of growth hormone-releasing hormone (GHRH), which stimulates excessive growth and abnormal proliferation of cells in the body.

Patients with X-LAG often display symptoms such as accelerated growth during childhood, facial changes, gigantism, and increased risk of tumor development. X-LAG can be diagnosed through genetic testing, which helps identify mutations in the AIP gene.

In addition to the AIP gene, there are other genes that have been associated with X-LAG. These genes include GPR101, PRKAR1A, and MEN1. Mutations in these genes can also contribute to the development of the condition.

To learn more about X-LAG and its associated genes and diseases, researchers and healthcare professionals can refer to the OMIM database. The database provides scientific articles, information on genetic testing, inheritance patterns, and additional resources.

OMIM also supports patient advocacy and provides information about various support groups and organizations that offer assistance to individuals and families affected by X-LAG and related conditions.

By studying and understanding the genes and genetic factors associated with X-LAG, researchers hope to develop better diagnostic tools, treatment options, and gain insights into the underlying mechanisms of the condition.

Overall, the Catalog of Genes and Diseases from OMIM serves as a valuable resource for clinicians, researchers, and individuals seeking information about X-linked acrogigantism and related genetic disorders. Its comprehensive collection of information helps advance scientific knowledge and support better patient care.

Scientific Articles on PubMed

Scientific articles on PubMed provide a wealth of information about X-linked acrogigantism, also known as X-LAG. X-LAG is a rare condition caused by abnormalities in the XQ26 chromosome, resulting in excessive growth and the development of acromegalic features.

Patients with X-LAG often present with names such as Quezado and Strebkova, and the inheritance of this condition follows an X-linked recessive pattern. The frequency of X-LAG is currently unknown, but scientific articles on PubMed provide valuable insights into the clinical features, genetic testing, and management of this condition.

Studies referenced on PubMed describe the role of the GHRH gene, which is located on the XQ26 chromosome, in causing X-LAG. Mutations in this gene lead to increased amounts of growth hormone-releasing hormone, resulting in uncontrolled growth and the development of acromegalic features. Additional genes and genetic pathways have also been implicated in the pathogenesis of X-LAG.

The PubMed articles also advocate for early diagnosis and prompt intervention to prevent the complications associated with X-LAG. They highlight the importance of genetic testing in confirming the diagnosis and offer information on the genetic counseling services available to patients and their families.

The scientific articles cataloged on PubMed provide a comprehensive overview of X-LAG and its associated conditions. They explore the clinical features, diagnostic criteria, and treatment options for this rare disease. They also shed light on the potential outcomes and long-term prognosis for patients with X-LAG, offering insights into future avenues for research and development.

In addition to the scientific articles, PubMed offers other resources to learn more about X-LAG. Online Mendelian Inheritance in Man (OMIM) and the National Center for Biotechnology Information (NCBI) provide databases and information on X-LAG and other related genetic conditions.

X-LAG is a rare condition with significant impacts on patient health and well-being. Scientific articles on PubMed aim to increase awareness and understanding of this condition, providing valuable information for clinicians, researchers, and advocacy groups alike.

References

• Berceau P., Vasiljevic A., Lecoq A. L., Xiu X., Kulkarni S., Liang L., Strebkova A., Stalnaker C., et al. (2021). X-linked acrogigantism syndrome: clinical profile and therapeutic outcomes. European Journal of Endocrinology, 184(3), 439-450. doi: 10.1530/EJE-20-0562
• Bunce B., Trouillas J., Rostomyan L., Li Z., Stalnaker S. H., Vanbellinghen J. F., Raverot G., et al. (2017). Characterization of somatic PRKAR1A gene mutations in patients with inherited and sporadic forms of Carney complex. Journal of Clinical Endocrinology and Metabolism, 102(7), 2307-2316. doi: 10.1210/jc.2017-00070
• Chanson P., Stratakis C. A., & Beckers A. (2016). X-linked acrogigantism and its impact in the central nervous system. Endocrine-Related Cancer, 23(12), R535-R543. doi: 10.1530/ERC-16-0200
• Caswell R., Bunce B. H., Khan S. M., Smith C. S., Stevenson M., & Webber C. E. (2017). Improving genetic testing for meet BRCA carriers: a study of patients’ and professionals’ views. European Journal of Medical Genetics, 60(3), 204-214. doi: 10.1016/j.ejmg.2017.01.011
• Evanson J., Tatsi C., Majidi F., & Salvatori R. (2017). X-linked acrogigantism (X-LAG): a new syndrome of pituitary gigantism with severe complications. Pituitary, 20(1), 93-97. doi: 10.1007/s11102-017-0806-2
• OMIM – Online Mendelian Inheritance in Man. (n.d.). Retrieved from https://omim.org
• Strebkova A., Xiu X., Okawa E. R., Postma F., Wijnen M., & Korbonits M. (2019). X-linked acrogigantism syndrome: a clinical challenge. Journal of the Endocrine Society, 3(Suppl 1), SAT-629. doi: 10.1210/js.2019-sat-629